Is Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) a buy in 2026?
No. Bullfrog AI Holdings, Inc. is one to avoid for now, per the Compass.
A $14M microcap with a real AI platform strapped to a cash-burning glioblastoma pipeline, but the math on survival doesn't work.
Where BFRG is headed
Bullfrog AI is two companies wearing one ticker. There's bfLEAP, a genuinely interesting AI/ML platform doing multi-modal analysis of preclinical and clinical datasets, sitting on a foundation of licensing deals with Johns Hopkins and a partnership with the Lieber Institute for Brain Development. And there's a preclinical-to-Phase-1 oncology pipeline led by BF-222, a repurposed mebendazole formulation aimed at glioblastoma, which is one of the hardest tumors in medicine to treat and a graveyard for small biotechs. By late 2027, one of those two identities has to dominate. The company can't fund both.
Read the full Compass Direction on BFRG
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $0.69).
See the full BFRG analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) a buy in 2026?
No. Bullfrog AI Holdings, Inc. is one to avoid for now, per the Compass. A $14M microcap with a real AI platform strapped to a cash-burning glioblastoma pipeline, but the math on survival doesn't work.
What is BFRG's Compass Score?
Bullfrog AI Holdings, Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for BFRG?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the BFRG page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.